Concenter BioPharma/Silkim Ltd.

Developing Novel Drugs for TYPE 2 DIABETES, IBD and PSORIASIS based on a Core-Technology-Platform, Utilizing the 505(b)(2) Pathway (IND Phase)

  • Stage Product In Development
  • Industry Biotechnology
  • Location Jerusalem, Israel
  • Currency USD
  • Founded January 2014
  • Employees 6
  • Incorporation Type Other
  • Website concenterbiopharma.com

Only investors on Gust who have been granted access can view this content.

Interested in this startup? Sign In or Sign Up to request more information.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free